Wiseheart Medval

Wiseheart Medval (Beijing Huixin Wiseheart Medval Biotechnology) is a clinical-stage biopharmaceutical company specializing in innovative cell therapies for neurodegenerative diseases. Founded in 2021 by Professor Zhiguo Chen of Xuanwu Hospital, the company leverages a proprietary non-integrative reprogramming platform to directly induce somatic cells into neural stem cells (iNSCs). This direct reprogramming approach bypasses the pluripotent stage, significantly reducing the risk of tumorigenicity and enhancing therapeutic safety. Its lead program, iNSC-DAP, is an autologous cell therapy for Parkinson's disease that achieved a global milestone with its first human transplantation in 2023. Headquartered in Beijing's Zhongguancun Life Science Park, Wiseheart Medval is supported by leading venture capital firms including Jingneng Green Fund and Beijing Venture Capital.